{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005830","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.908461+00:00","generated_at":"2026-06-18T15:57:24.561692+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Terns Pharma completes NASH trial enrollment, on track for CML and obesity trials in H2 2023","bullets":["Completed enrollment in Phase 2a DUET trial of TERN-501 (THR-β agonist) for NASH; top-line data expected Q3 2023.","On track to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in H2 2023; China Phase 1 update at major oncology conference.","IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; first-in-human obesity trial expected H2 2023 with top-line data in 2024.","FDA Type C meeting scheduled for May 2023 to discuss non-invasive endpoints for NASH development.","Adjusted cash balance of $293M (including $112M Dec 2022 equity financing) expected to provide runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005830","json":"https://secwatch.observer/filing/0000950170-23-005830.json","markdown":"https://secwatch.observer/filing/0000950170-23-005830.md","text":"https://secwatch.observer/filing/0000950170-23-005830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023005830/0000950170-23-005830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023005830/tern-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:57:24.561692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}